Fig. 2: TRIP13 is crucial for TNFR2-mediated Treg proliferation in vivo in the inflammatory context. | Cell Death & Disease

Fig. 2: TRIP13 is crucial for TNFR2-mediated Treg proliferation in vivo in the inflammatory context.

From: TRIP13 promotes the expansion and immunosuppression of CD4+Foxp3+ regulatory T cells by sustaining HAT1 stability

Fig. 2

A Schematic diagram of experimental procedure. FCM analysis shows the proportion (B, C, F, G), number of colonic Tregs (D and H), and expression of Ki-67 (E and I) after LV5-NC or LV5-Trip13 treatment in WT and TNFR2 KO mice. The proportion (J and K) and number of colonic Tregs (L) after i.p. injection with Trip13 shRNA or LV5-Tnfr2 or control for 3 days were shown. The development of colitis (M–O), proportion (P), and number of colonic Tregs (Q) after colitis induction by TNBS in Foxp3YFP-cre and Trip13 fl/flFoxp3YFP-cre mice were shown. Typical FCM plots display the proportion of gated cells. R, S The immunosuppression of Tregs in Trip13 fl/flFoxp3YFP-cre mice was determined. Representative FCM histogram (R, the numbers indicate the proportion of replicating cells (%) and the division index), and the summary of the division index (S), were shown. Data are presented as means ± SEM from 3 mice per group and are representative of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001. n.s. no significant differences.

Back to article page